Table 1.

Cohort characteristics: differences were calculated by Kruskal–Wallis test; IQR, interquartile range; BMI, Body Mass Index.

Patients (Samples)		Hospitalized Patients (n = 10)	Convalescent Patients (n = 24)	Control Collective (n = 13)	p-Value
Patient Characteristics	Age, years median (IQR)	56.5 (54–63)	56 (55–58)	54 (51–57)	0.08
	Gender, male (%)	10 (100)	22 (91.6)	4 (31)	0.046
	BMI (IQR)	23.8 (22–25.9)	26.1 (22.8–28.1)	22.3 (20.2–25.7)	0.161
	Invasive Vent. (%)	0 (0)	0 (0)	0 (0)	1
	Oxygen therapy (%)	0 (0)	0 (0)	0 (0)	1
	Death (abs.)	0 (0)	0 (0)	0 (0)	1
	Interval 1. symptom to blood sample, days (IQR)	6 (2–17)	88 (70–135)		<0.001
SARS CoV-2 therapy	Remdesivir (5 days)	1 (10)	0 (0)	0 (0)	0.151
	Dexamethasone (6 mg, 10 days)	2 (20)	0 (0)	0 (0)	0.021
Pre-existing conditions	Chronic inflammatory disease (%)	4 (40)	0 (0)	0 (0)	<0.001
	Respiratory disease (%)	3 (30)	0 (0)	0 (0)	0.003
	Kidney insufficiency (%)	1 (10)	0 (0)	0 (0)	0.151
	Metastatic neoplasm (%)	1 (10)	0 (0)	0 (0)	0.151
	Diabetes (%)	1 (10)	0 (0)	0 (0)	0.151
	Arterial hypertension (%)	4 (40)	0 (0)	0 (0)	<0.001
	Coronary heart disease (%)	2 (20)	0 (0)	0 (0)	0.021
Medication	Angiotensin-1 receptor antagonist (%)	1 (10)	0 (0)	0 (0)	0.151
	Angiotensin converting enzyme inhibitor (%)	2 (10)	0 (0)	0 (0)	0.021